28Jul 2023
Efficacy of Donanemab in Patients With Early Symptomatic Alzheimer Disease

Efficacy of Donanemab in Patients With Early Symptomatic Alzheimer Disease

The study involved 1736 participants from 8 countries with mild cognitive impairment or mild dementia. Donanemab demonstrated efficacy in both low/medium tau and combined tau pathology populations, as evidenced by significant improvements in Alzheimer Disease Rating Scale and Clinical Dementia Rating Scale scores compared to the placebo group. However, some adverse events, including amyloid-related imaging abnormalities and infusion-related reactions, were observed. Despite this, the study marks a significant step forward in Alzheimer's research, offering hope for improved treatment options.

  • #oncology

Like

Save

Share